A Phase 2 interventional study of Remibrutinib and Placebo in Sjögren Syndrome, sponsored by Novartis Pharmaceuticals. Terminated at 26 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-01-30.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Sjogren's Syndrome by Novartis — 2 open to participants now, 4 under way, 3 of them phase 3. Sjogren's Syndrome · Novartis.
Among the 15 studies in Sjogren's Syndrome by Novartis, this one is the 10th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2019, is one of 9 in phase 2, and was the 5th registered.
330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.
Browse Sjogren's Syndrome studies →2 of the 15 studies in Sjogren's Syndrome by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Australia, Canada and 6 more countries
Ages 18–100
Novartis Pharmaceuticals · Sites in United States, Australia, Austria and 17 more countries
Ages 18+
By country, each count listing its studies:
Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 10 · Phase 3 4
First in 2014; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 73 is above the median of 50 across 218 interventional studies indexed under Sjogren's Syndrome.
Median enrollment 240 across the 14 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Sjogren's Syndrome by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was an adaptive design phase 2 study to establish safety and efficacy; and to characterize the dose-response of LOU064 in subjects with moderate to severe Sjögren's syndrome. LOU064 is an oral Bruton's tyrosine kinase (BTK) inhibitor.
This study was planned as an adaptive Phase 2 randomized, double-blind, placebo-controlled, multi-center, integrated dose-ranging study to evaluate the safety and efficacy of multiple remibrutinib doses in patients with moderate to severe Sjögren's Syndrome.
Of the initially planned two parts, only Part 1 of the study was conducted. In Part 1, the highest expected biologically active single dose of remibrutinib (100 mg) was tested in two different dosing regimens, a once daily dose (qd) or twice daily dose (bid), and compared to the placebo group. Each patient in Part 1 of the study underwent a screening period of up to 6 weeks, a treatment period of 24 weeks, and a follow-up period of 30 days post-treatment before the End of Study (EOS) visit. The total duration for each patient in the study, including Screening, was up to 35 weeks. For the treatment period, patients were randomized in a 1:1:1 ratio to one of the 3 treatment groups: remibrutinib 100 mg bid, remibrutinib 100 mg qd and placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Remibrutinib 100 mg twice daily (bid)
Drug: Remibrutinib
Remibrutinib 100 mg once daily (qd)
Drug: Remibrutinib · Drug: Placebo
Placebo group
Drug: Placebo
Remibrutinib 100 mg was administered orally as two 50 mg hard gelatin capsules. Patients in the remibrutinib 100 mg bid dose group took 2 capsules of active medication in the morning and 2 capsules of active medication in the evening. Patients in the remibrutinib 100 mg qd dose group took 2 capsules of active medication in the morning and 2 capsules of the placebo in the evening.
Also known as: LOU064
Placebo was administered orally as two hard gelatin capsules. Patients in the placebo dose group took 2 capsules of placebo in the morning and 2 capsules of placebo in the evening.
Change From Baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Total Score at Week 24
ESSDAI is a validated disease outcome measure for Sjögren's Syndrome. The instrument contains 12 organ-specific domains contributing to disease activity: constitutional, lymphadenopathy, glandular, articular, cutaneous, pulmonary, renal, muscular, peripheral nervous system, central nervous system, hematological and biological. For each domain, features of disease activity were scored according to their severity. These scores were summed across the 12 domains in a weighted manner to provide the total score. ESSDAI total score ranges from 0 to 123 with higher values indicating more disease activity. A negative change from baseline indicates improvement. The baseline value is defined as the last assessment performed prior to administration of the first dose of study treatment. A mixed effect model for repeated measurements (MMRM) was fitted to the changes from baseline in ESSDAI for all post-baseline time points up to Week 24. Values estimated from the model are presented in this table.
Time frame: Baseline, Week 24
Change From Baseline in ESSDAI Total Score Over Time
ESSDAI is a validated disease outcome measure for Sjögren's Syndrome. The instrument contains 12 organ-specific domains contributing to disease activity: constitutional, lymphadenopathy, glandular, articular, cutaneous, pulmonary, renal, muscular, peripheral nervous system, central nervous system, hematological and biological. For each domain, features of disease activity were scored according to their severity. These scores were summed across the 12 domains in a weighted manner to provide the total score. ESSDAI total score ranges from 0 to 123 with higher values indicating more disease activity. A negative change from baseline indicates improvement. The baseline value is defined as the last assessment performed prior to administration of the first dose of study treatment. A mixed effect model for repeated measurements (MMRM) was fitted to the changes from baseline in ESSDAI for all post-baseline time points up to Week 24. Values estimated from the model are presented in this table.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20
Change From Baseline in EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) Total Score Over Time
ESSPRI is an established disease outcome measure for Sjögren's Syndrome. It consists of three domains of dryness, pain, and fatigue. The patient can assess the severity of symptoms they experience on a single 0-10 numerical scale for each of the three domains. The ESSPRI score is defined as the mean of scores from the three scales: (dryness + pain +fatigue) /3. ESSPRI total score ranges from 0 to 10 with higher values indicating more disease symptoms. A negative change from baseline indicates improvement. The baseline value is defined as the last assessment performed prior to administration of the first dose of study treatment. A mixed effect model for repeated measurements (MMRM) was fitted to the changes from baseline in ESSPRI for all post-baseline time points up to Week 24. Values estimated from the model are presented in this table.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20 and Week 24
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F) Total Score Over Time
FACIT-F v4 is a short, 13-item, easy-to-administer tool that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue was measured on a 5-point Likert scale (0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much). FACIT-F total score ranges from 0 to 52 with higher values indicating higher quality of life (less fatigue). A positive change from baseline is a favorable outcome. The baseline value is defined as the last assessment performed prior to administration of the first dose of study treatment. A mixed effect model for repeated measurements (MMRM) was fitted to the changes from baseline in FACIT-F for all post-baseline time points up to Week 24. Values estimated from the model are presented in this table.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20 and Week 24
Change From Baseline in EuroQual 5 Dimensions (EQ-5D) VAS Score Over Time
EQ-5D is a standardized instrument that measures the health-related quality of life. The EQ-5D consists of a descriptive system and a visual analog scale (VAS).The EQ-5D VAS records the patient's self-rated health on a vertical visual analogue scale with 0 representing 'Worst imaginable Health State' and 100 'Best imaginable Health State'. A positive change from baseline is a favorable outcome. The baseline value is defined as the last assessment performed prior to administration of the first dose of study treatment. A mixed effect model for repeated measurements (MMRM) was fitted to the changes from baseline in EQ-5D VAS score for all post-baseline time points up to Week 24. Values estimated from the model are presented in this table.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20 and Week 24
Change From Baseline in Physician Global Assessment Scale (PhGA) Score Over Time
The physician's global assessment scale was used for the Investigator to rate the disease activity of their patient using 100 mm visual analog scale (VAS) ranging from "no disease activity" (0) to "maximal disease activity" (100). A negative change from baseline indicates improvement. The baseline value is defined as the last assessment performed prior to administration of the first dose of study treatment. A mixed effect model for repeated measurements (MMRM) was fitted to the changes from baseline in PhGA score for all post-baseline time points up to Week 24. Values estimated from the model are presented in this table.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20 and Week 24
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
Number of participants with TEAEs and serious TEAEs, including changes from baseline in vital signs, electrocardiograms and laboratory results qualifying and reported as TEAEs. TEAEs are defined as adverse events that started after the first dose of study medications or adverse events present prior to start of double-blind treatment but increased in severity. The number of participants in each category is reported in the table.
Time frame: From first dose of study treatment up 30 days after last dose (Week 29)
Maximum Observed Blood Concentration (Cmax) of Remibrutinib at Week 4
Remibrutinib was determined in whole blood by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. Cmax is defined as the maximum (peak) observed blood concentration following a dose.
Time frame: pre-dose, 0.5, 1, 2, 3 and 4 hours post-dose at Week 4
Maximum Observed Blood Concentration (Cmax) of Remibrutinib at Week 24
Remibrutinib was determined in whole blood by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. Cmax is defined as the maximum (peak) observed blood concentration following a dose.
Time frame: pre-dose, 0.5, 1, 2, 3 and 4 hours post-dose at Week 24
Time to Reach Maximum Observed Blood Concentration (Tmax) of Remibrutinib at Week 4
Remibrutinib was determined in whole blood by a validated LC-MS/MS method with a LLOQ of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. Tmax is defined as the time to reach maximum (peak) blood concentration following a dose.
Time frame: pre-dose, 0.5, 1, 2, 3 and 4 hours post-dose at Week 4
Time to Reach Maximum Observed Blood Concentration (Tmax) of Remibrutinib at Week 24
Remibrutinib was determined in whole blood by a validated LC-MS/MS method with a LLOQ of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. Tmax is defined as the time to reach maximum (peak) blood concentration following a dose.
Time frame: pre-dose, 0.5, 1, 2, 3 and 4 hours post-dose at Week 24
Area Under the Blood Concentration-time Curve Within a Dosing Interval (Tau) at Steady-state (AUCtau) of Remibrutinib at Week 4
Remibrutinib was determined in whole blood by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. AUCtau is defined as the area under the blood concentration-time curve calculated/extrapolated to the end of a dosing interval (tau) at steady-state. Tau was 24 hours for the qd dosing group and 12 hours for the bid dosing group. For the calculation of AUCtau, the pre-dose concentrations at Week 4 and Week 24 were duplicated as 24 hours and 12 hours concentrations for the qd and bid groups, respectively. The linear trapezoidal method was used for AUCtau calculation.
Time frame: pre-dose, 0.5, 1, 2, 3 and 4 hours post-dose at Week 4
Area Under the Blood Concentration-time Curve Within a Dosing Interval (Tau) at Steady-state (AUCtau) of Remibrutinib at Week 24
Remibrutinib was determined in whole blood by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. AUCtau is defined as the area under the blood concentration-time curve calculated/extrapolated to the end of a dosing interval (tau) at steady-state. Tau was 24 hours for the qd dosing group and 12 hours for the bid dosing group. For the calculation of AUCtau, the pre-dose concentrations at Week 4 and Week 24 were duplicated as 24 hours and 12 hours concentrations for the qd and bid groups, respectively. The linear trapezoidal method was used for AUCtau calculation.
Time frame: pre-dose, 0.5, 1, 2, 3 and 4 hours post-dose at Week 24
Area Under the Blood Concentration-time Curve From Time Zero to 4 Hours Post-dose (AUC0-4h) of Remibrutinib at Week 4
Remibrutinib was determined in whole blood by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. AUC0-4h is defined as the area under the blood concentration-time curve from time zero to 4 hours post-dose, which was the last sampling time. The linear trapezoidal method was used for AUC0-4h calculation.
Time frame: pre-dose, 0.5, 1, 2, 3 and 4 hours post-dose at Week 4
Area Under the Blood Concentration-time Curve From Time Zero to 4 Hours Post-dose (AUC0-4h) of Remibrutinib at Week 24
Remibrutinib was determined in whole blood by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. AUC0-4h is defined as the area under the blood concentration-time curve from time zero to 4 hours post-dose, which was the last sampling time. The linear trapezoidal method was used for AUC0-4h calculation.
Time frame: pre-dose, 0.5, 1, 2, 3 and 4 hours post-dose at Week 24
Elimination Half-life (T1/2) of Remibrutinib at Week 4
Remibrutinib was determined in whole blood by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. T1/2 is defined as the time taken for the blood concentration, as well as the amount of the drug in the body, to fall by one-half.
Time frame: pre-dose, 0.5, 1, 2, 3 and 4 hours post-dose at Week 4
Elimination Half-life (T1/2) of Remibrutinib at Week 24
Remibrutinib was determined in whole blood by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. T1/2 is defined as the time taken for the blood concentration, as well as the amount of the drug in the body, to fall by one-half.
Time frame: pre-dose, 0.5, 1, 2, 3 and 4 hours post-dose at Week 24
Participants took part in 26 investigative sites in 12 countries.
| Milestone | Remibrutinib 100 mg Bid | Remibrutinib 100 mg qd | Placebo |
|---|---|---|---|
| Started | 24 | 25 | 24 |
| Completed | 17 | 17 | 21 |
| Not completed | 7 | 8 | 3 |
| Withdrew: Adverse event | 3 | 4 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Physician decision | 2 | 1 | 1 |
| Withdrew: Subject decision | 2 | 2 | 0 |
ESSDAI is a validated disease outcome measure for Sjögren's Syndrome. The instrument contains 12 organ-specific domains contributing to disease activity: constitutional, lymphadenopathy, glandular, articular, cutaneous, pulmonary, renal, muscular, peripheral nervous system, central nervous system, hematological and biological. For each domain, features of disease activity were scored according to their severity. These scores were summed across the 12 domains in a weighted manner to provide the total score. ESSDAI total score ranges from 0 to 123 with higher values indicating more disease activity. A negative change from baseline indicates improvement. The baseline value is defined as the last assessment performed prior to administration of the first dose of study treatment. A mixed effect model for repeated measurements (MMRM) was fitted to the changes from baseline in ESSDAI for all post-baseline time points up to Week 24. Values estimated from the model are presented in this table.
| score on scale | Remibrutinib 100 mg qd | Remibrutinib 100 mg Bid | Any Remibrutinib | Placebo |
|---|---|---|---|---|
| Change From Baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Total Score at Week 24 | -4.70 ± 0.78 | -3.70 ± 0.80 | -4.20 ± 0.56 | -1.34 ± 0.74 |
ESSDAI is a validated disease outcome measure for Sjögren's Syndrome. The instrument contains 12 organ-specific domains contributing to disease activity: constitutional, lymphadenopathy, glandular, articular, cutaneous, pulmonary, renal, muscular, peripheral nervous system, central nervous system, hematological and biological. For each domain, features of disease activity were scored according to their severity. These scores were summed across the 12 domains in a weighted manner to provide the total score. ESSDAI total score ranges from 0 to 123 with higher values indicating more disease activity. A negative change from baseline indicates improvement. The baseline value is defined as the last assessment performed prior to administration of the first dose of study treatment. A mixed effect model for repeated measurements (MMRM) was fitted to the changes from baseline in ESSDAI for all post-baseline time points up to Week 24. Values estimated from the model are presented in this table.
| score on scale | Remibrutinib 100 mg qd | Remibrutinib 100 mg Bid | Any Remibrutinib | Placebo |
|---|---|---|---|---|
| Week 2 | -1.68 ± 0.52 | -1.05 ± 0.52 | -1.37 ± 0.37 | -0.37 ± 0.55 |
| Week 4 | -2.57 ± 0.60 | -2.54 ± 0.62 | -2.55 ± 0.43 | -0.79 ± 0.61 |
| Week 8 | -2.74 ± 0.72 | -2.93 ± 0.71 | -2.83 ± 0.51 | -2.36 ± 0.69 |
| Week 12 | -3.66 ± 0.74 | -2.56 ± 0.75 | -3.11 ± 0.53 | -1.92 ± 0.73 |
| Week 16 | -4.02 ± 0.71 | -2.57 ± 0.74 | -3.29 ± 0.51 | -2.16 ± 0.69 |
| Week 20 | -4.40 ± 0.73 | -3.26 ± 0.75 | -3.83 ± 0.52 | -1.84 ± 0.69 |
ESSPRI is an established disease outcome measure for Sjögren's Syndrome. It consists of three domains of dryness, pain, and fatigue. The patient can assess the severity of symptoms they experience on a single 0-10 numerical scale for each of the three domains. The ESSPRI score is defined as the mean of scores from the three scales: (dryness + pain +fatigue) /3. ESSPRI total score ranges from 0 to 10 with higher values indicating more disease symptoms. A negative change from baseline indicates improvement. The baseline value is defined as the last assessment performed prior to administration of the first dose of study treatment. A mixed effect model for repeated measurements (MMRM) was fitted to the changes from baseline in ESSPRI for all post-baseline time points up to Week 24. Values estimated from the model are presented in this table.
| score on scale | Remibrutinib 100 mg qd | Remibrutinib 100 mg Bid | Any Remibrutinib | Placebo |
|---|---|---|---|---|
| Week 2 | -0.44 ± 0.26 | 0.18 ± 0.26 | -0.13 ± 0.18 | -0.09 ± 0.27 |
| Week 4 | -0.72 ± 0.30 | -0.14 ± 0.30 | -0.43 ± 0.21 | -0.35 ± 0.30 |
| Week 8 | -0.83 ± 0.31 | -0.38 ± 0.31 | -0.60 ± 0.22 | -0.57 ± 0.29 |
| Week 12 | -0.88 ± 0.31 | -0.32 ± 0.31 | -0.60 ± 0.22 | -0.66 ± 0.29 |
| Week 16 | -0.77 ± 0.36 | -0.39 ± 0.37 | -0.58 ± 0.26 | -0.71 ± 0.34 |
| Week 20 | -0.92 ± 0.38 | -0.74 ± 0.39 | -0.83 ± 0.27 | -0.92 ± 0.36 |
| Week 24 | -1.17 ± 0.34 | -0.76 ± 0.35 | -0.96 ± 0.24 | -1.13 ± 0.31 |
FACIT-F v4 is a short, 13-item, easy-to-administer tool that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue was measured on a 5-point Likert scale (0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much). FACIT-F total score ranges from 0 to 52 with higher values indicating higher quality of life (less fatigue). A positive change from baseline is a favorable outcome. The baseline value is defined as the last assessment performed prior to administration of the first dose of study treatment. A mixed effect model for repeated measurements (MMRM) was fitted to the changes from baseline in FACIT-F for all post-baseline time points up to Week 24. Values estimated from the model are presented in this table.
| score on scale | Remibrutinib 100 mg qd | Remibrutinib 100 mg Bid | Any Remibrutinib | Placebo |
|---|---|---|---|---|
| Week 2 | 1.80 ± 1.32 | -0.51 ± 1.35 | 0.64 ± 0.95 | 3.37 ± 1.43 |
| Week 4 | 4.83 ± 1.50 | 3.97 ± 1.57 | 4.40 ± 1.09 | 3.51 ± 1.58 |
| Week 8 | 4.00 ± 1.64 | 3.79 ± 1.66 | 3.90 ± 1.17 | 5.26 ± 1.60 |
| Week 12 | 4.88 ± 1.80 | 4.25 ± 1.86 | 4.56 ± 1.30 | 7.30 ± 1.77 |
| Week 16 | 4.40 ± 1.97 | 3.29 ± 2.08 | 3.84 ± 1.44 | 7.73 ± 1.98 |
| Week 20 | 10.01 ± 2.20 | 4.32 ± 2.30 | 7.16 ± 1.60 | 5.77 ± 2.17 |
| Week 24 | 8.17 ± 2.45 | 4.64 ± 2.55 | 6.40 ± 1.77 | 7.45 ± 2.32 |
EQ-5D is a standardized instrument that measures the health-related quality of life. The EQ-5D consists of a descriptive system and a visual analog scale (VAS).The EQ-5D VAS records the patient's self-rated health on a vertical visual analogue scale with 0 representing 'Worst imaginable Health State' and 100 'Best imaginable Health State'. A positive change from baseline is a favorable outcome. The baseline value is defined as the last assessment performed prior to administration of the first dose of study treatment. A mixed effect model for repeated measurements (MMRM) was fitted to the changes from baseline in EQ-5D VAS score for all post-baseline time points up to Week 24. Values estimated from the model are presented in this table.
| score on scale | Remibrutinib 100 mg qd | Remibrutinib 100 mg Bid | Any Remibrutinib | Placebo |
|---|---|---|---|---|
| Week 2 | -3.05 ± 3.11 | -2.86 ± 3.16 | -2.95 ± 2.22 | -3.02 ± 3.28 |
| Week 4 | -1.74 ± 2.71 | -0.03 ± 2.86 | -0.88 ± 1.97 | 2.99 ± 2.87 |
| Week 8 | 1.46 ± 3.20 | 1.76 ± 3.20 | 1.61 ± 2.26 | 3.44 ± 3.04 |
| Week 12 | -2.36 ± 2.71 | 1.58 ± 2.82 | -0.39 ± 1.95 | 4.00 ± 2.64 |
| Week 16 | -0.44 ± 3.27 | 4.27 ± 3.54 | 1.92 ± 2.41 | 1.79 ± 3.28 |
| Week 20 | -0.91 ± 3.15 | 5.37 ± 3.33 | 2.23 ± 2.29 | 5.29 ± 3.01 |
| Week 24 | 1.81 ± 3.47 | 5.73 ± 3.65 | 3.77 ± 2.52 | 2.07 ± 3.22 |
The physician's global assessment scale was used for the Investigator to rate the disease activity of their patient using 100 mm visual analog scale (VAS) ranging from "no disease activity" (0) to "maximal disease activity" (100). A negative change from baseline indicates improvement. The baseline value is defined as the last assessment performed prior to administration of the first dose of study treatment. A mixed effect model for repeated measurements (MMRM) was fitted to the changes from baseline in PhGA score for all post-baseline time points up to Week 24. Values estimated from the model are presented in this table.
| score on scale | Remibrutinib 100 mg qd | Remibrutinib 100 mg Bid | Any Remibrutinib | Placebo |
|---|---|---|---|---|
| Week 2 | -4.21 ± 2.90 | -4.02 ± 2.85 | -4.12 ± 2.04 | -4.82 ± 3.10 |
| Week 4 | -9.58 ± 2.89 | -8.93 ± 2.96 | -9.26 ± 2.08 | -7.28 ± 2.95 |
| Week 8 | -13.68 ± 3.39 | -13.78 ± 3.28 | -13.73 ± 2.37 | -13.23 ± 3.16 |
| Week 12 | -13.85 ± 3.63 | -9.45 ± 3.68 | -11.65 ± 2.60 | -17.67 ± 3.52 |
| Week 16 | -19.37 ± 3.61 | -7.25 ± 3.74 | -13.31 ± 2.61 | -15.90 ± 3.51 |
| Week 20 | -23.56 ± 3.43 | -17.31 ± 3.48 | -20.43 ± 2.45 | -17.57 ± 3.20 |
| Week 24 | -21.25 ± 3.88 | -13.15 ± 3.95 | -17.20 ± 2.78 | -20.15 ± 3.54 |
Number of participants with TEAEs and serious TEAEs, including changes from baseline in vital signs, electrocardiograms and laboratory results qualifying and reported as TEAEs. TEAEs are defined as adverse events that started after the first dose of study medications or adverse events present prior to start of double-blind treatment but increased in severity. The number of participants in each category is reported in the table.
| Participants | Remibrutinib 100 mg Bid | Remibrutinib 100 mg qd | Placebo |
|---|---|---|---|
| TEAE | 22 | 21 | 20 |
| Study drug-related TEAE | 10 | 8 | 9 |
| Serious TEAE | 1 | 1 | 1 |
Remibrutinib was determined in whole blood by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. Cmax is defined as the maximum (peak) observed blood concentration following a dose.
| ng/mL | Remibrutinib 100 mg Bid | Remibrutinib 100 mg qd |
|---|---|---|
| Maximum Observed Blood Concentration (Cmax) of Remibrutinib at Week 4 | 183 ± 82.5 | 225 ± 154 |
Remibrutinib was determined in whole blood by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. Cmax is defined as the maximum (peak) observed blood concentration following a dose.
| ng/mL | Remibrutinib 100 mg Bid | Remibrutinib 100 mg qd |
|---|---|---|
| Maximum Observed Blood Concentration (Cmax) of Remibrutinib at Week 24 | 224 ± 202 | 169 ± 77.9 |
Remibrutinib was determined in whole blood by a validated LC-MS/MS method with a LLOQ of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. Tmax is defined as the time to reach maximum (peak) blood concentration following a dose.
| hours | Remibrutinib 100 mg Bid | Remibrutinib 100 mg qd |
|---|---|---|
| Time to Reach Maximum Observed Blood Concentration (Tmax) of Remibrutinib at Week 4 | 1.00 (0.500 to 3.00) | 1.00 (0.500 to 4.00) |
Remibrutinib was determined in whole blood by a validated LC-MS/MS method with a LLOQ of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. Tmax is defined as the time to reach maximum (peak) blood concentration following a dose.
| hours | Remibrutinib 100 mg Bid | Remibrutinib 100 mg qd |
|---|---|---|
| Time to Reach Maximum Observed Blood Concentration (Tmax) of Remibrutinib at Week 24 | 1.00 (0.500 to 3.00) | 1.00 (0.500 to 3.08) |
Remibrutinib was determined in whole blood by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. AUCtau is defined as the area under the blood concentration-time curve calculated/extrapolated to the end of a dosing interval (tau) at steady-state. Tau was 24 hours for the qd dosing group and 12 hours for the bid dosing group. For the calculation of AUCtau, the pre-dose concentrations at Week 4 and Week 24 were duplicated as 24 hours and 12 hours concentrations for the qd and bid groups, respectively. The linear trapezoidal method was used for AUCtau calculation.
| h*ng/mL | Remibrutinib 100 mg Bid | Remibrutinib 100 mg qd |
|---|---|---|
| Area Under the Blood Concentration-time Curve Within a Dosing Interval (Tau) at Steady-state (AUCtau) of Remibrutinib at Week 4 | 569 ± 311 | 1020 ± 700 |
Remibrutinib was determined in whole blood by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. AUCtau is defined as the area under the blood concentration-time curve calculated/extrapolated to the end of a dosing interval (tau) at steady-state. Tau was 24 hours for the qd dosing group and 12 hours for the bid dosing group. For the calculation of AUCtau, the pre-dose concentrations at Week 4 and Week 24 were duplicated as 24 hours and 12 hours concentrations for the qd and bid groups, respectively. The linear trapezoidal method was used for AUCtau calculation.
| h*ng/mL | Remibrutinib 100 mg Bid | Remibrutinib 100 mg qd |
|---|---|---|
| Area Under the Blood Concentration-time Curve Within a Dosing Interval (Tau) at Steady-state (AUCtau) of Remibrutinib at Week 24 | 670 ± 380 | 636 ± 306 |
Remibrutinib was determined in whole blood by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. AUC0-4h is defined as the area under the blood concentration-time curve from time zero to 4 hours post-dose, which was the last sampling time. The linear trapezoidal method was used for AUC0-4h calculation.
| h*ng/mL | Remibrutinib 100 mg Bid | Remibrutinib 100 mg qd |
|---|---|---|
| Area Under the Blood Concentration-time Curve From Time Zero to 4 Hours Post-dose (AUC0-4h) of Remibrutinib at Week 4 | 351 ± 169 | 393 ± 207 |
Remibrutinib was determined in whole blood by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. AUC0-4h is defined as the area under the blood concentration-time curve from time zero to 4 hours post-dose, which was the last sampling time. The linear trapezoidal method was used for AUC0-4h calculation.
| h*ng/mL | Remibrutinib 100 mg Bid | Remibrutinib 100 mg qd |
|---|---|---|
| Area Under the Blood Concentration-time Curve From Time Zero to 4 Hours Post-dose (AUC0-4h) of Remibrutinib at Week 24 | 420 ± 259 | 317 ± 144 |
Remibrutinib was determined in whole blood by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. T1/2 is defined as the time taken for the blood concentration, as well as the amount of the drug in the body, to fall by one-half.
| hours | Remibrutinib 100 mg Bid | Remibrutinib 100 mg qd |
|---|---|---|
| Elimination Half-life (T1/2) of Remibrutinib at Week 4 | 3.08 ± 0.998 | 3.86 ± 2.28 |
Remibrutinib was determined in whole blood by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. T1/2 is defined as the time taken for the blood concentration, as well as the amount of the drug in the body, to fall by one-half.
| hours | Remibrutinib 100 mg Bid | Remibrutinib 100 mg qd |
|---|---|---|
| Elimination Half-life (T1/2) of Remibrutinib at Week 24 | 3.15 ± 0.907 | 3.88 ± 1.95 |
Collected over From first dose of study treatment up 30 days after last dose (Week 29). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Remibrutinib 100 mg Bid | 0/24 (0%) | 1/24 (4.2%) | 15/24 (62.5%) |
| Remibrutinib 100 mg qd | 0/25 (0%) | 1/25 (4%) | 12/25 (48%) |
| Any Remibrutinib | 0/49 (0%) | 2/49 (4.1%) | 27/49 (55.1%) |
| Placebo | 0/24 (0%) | 1/24 (4.2%) | 17/24 (70.8%) |
| Total | 0/73 (0%) | 3/73 (4.1%) | 44/73 (60.3%) |
| Event | Remibrutinib 100 mg Bid | Remibrutinib 100 mg qd | Any Remibrutinib | Placebo | Total |
|---|---|---|---|---|---|
| COVID-19 pneumoniaInfections and infestations | 1/24 | 0/25 | 1/49 | 0/24 | 1/73 |
| PneumoniaInfections and infestations | 0/24 | 0/25 | 0/49 | 1/24 | 1/73 |
| Herpes zosterInfections and infestations | 0/24 | 1/25 | 1/49 | 0/24 | 1/73 |
| Event | Remibrutinib 100 mg Bid | Remibrutinib 100 mg qd | Any Remibrutinib | Placebo | Total |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 1/24 | 3/25 | 4/49 | 5/24 | 9/73 |
| NauseaGastrointestinal disorders | 4/24 | 1/25 | 5/49 | 2/24 | 7/73 |
| LeukopeniaBlood and lymphatic system disorders | 0/24 | 0/25 | 0/49 | 3/24 | 3/73 |
| LymphopeniaBlood and lymphatic system disorders | 0/24 | 0/25 | 0/49 | 3/24 | 3/73 |
| FatigueGeneral disorders | 3/24 | 0/25 | 3/49 | 2/24 | 5/73 |
| NasopharyngitisInfections and infestations | 2/24 | 1/25 | 3/49 | 3/24 | 6/73 |
| Upper respiratory tract infectionInfections and infestations | 3/24 | 0/25 | 3/49 | 2/24 | 5/73 |
| NeutropeniaBlood and lymphatic system disorders | 1/24 | 1/25 | 2/49 | 2/24 | 4/73 |
| Abdominal distensionGastrointestinal disorders | 0/24 | 0/25 | 0/49 | 2/24 | 2/73 |
| DiarrhoeaGastrointestinal disorders | 2/24 | 0/25 | 2/49 | 1/24 | 3/73 |
| Age, Continuous(years) | Remibrutinib 100 mg Bid | Remibrutinib 100 mg qd | Placebo | Total |
|---|---|---|---|---|
| Mean | 49.5 ± 15.21 | 54.8 ± 10.51 | 51.0 ± 13.94 | 51.8 ± 13.34 |
| Sex: Female, Male(Participants) | Remibrutinib 100 mg Bid | Remibrutinib 100 mg qd | Placebo | Total |
|---|---|---|---|---|
| Female | 24 | 24 | 23 | 71 |
| Male | 0 | 1 | 1 | 2 |
| Race/Ethnicity, Customized(Participants) | Remibrutinib 100 mg Bid | Remibrutinib 100 mg qd | Placebo | Total |
|---|---|---|---|---|
| Asian | 7 | 7 | 7 | 21 |
| White | 17 | 17 | 16 | 50 |
| Unknown | 0 | 1 | 0 | 1 |
| Black or African American | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Jul 2019 to primary completion in Nov 2021, 28 months.
Results were first posted in Dec 2022, 1 year after primary completion. A results delay was requested in Aug 2022.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Remibrutinib